Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Bo Zhao (NPI 1245464742)

Field	Value
Entity Type	Individual
Organization	Bo Zhao
Address	500 Sentara Cir Ste 203
City	Williamsburg
State	VA
ZIP	23188
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 12, 2009

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

This provider is a Hematology & Oncology physician whose Medicare billing is heavily driven by high-volume oncology biologics: J9271 (24K claims, $1M revenue, 42.6% of Medicare revenue), J9299 (17.7K claims, $425.8K revenue, 17.6%), and J0897 (20.5K claims, $369.4K revenue, 15.2%). The top three Medicare codes by revenue account for 75.4% of this provider's total Medicare revenue, signaling an operational focus on infusion-delivered, high-utilization cancer therapies rather than a broad mix of unrelated services.

The provider's lifetime Medicare revenue is $2.6M and there is no Medicaid billing on file, making this effectively a single-payer (Medicare) billing profile for the public programs in the dataset. The absence of Medicaid activity means payer-concentration considerations should focus on Medicare reimbursement trends and utilization for these oncology drugs.

Although J9271 is the single largest revenue driver ($1M, 42.6% of Medicare revenue), the provider ranks #247 of 1841 providers nationally for that code and is described as having "typical, unremarkable volume for this code" (86th percentile). Similarly, J9299 ($425.8K, 17.6%) is ranked #198 of 505 and labeled "typical, unremarkable volume for this code" (61th percentile), so the practice is not a national outlier for these checkpoint inhibitors but maintains solid utilization.

By contrast, J0897 (denosumab) shows a different competitive signal: 20.5K claims and $369.4K revenue with a national rank of #273 of 10057 and labeled "notably above typical national volume for this code" (97th percentile). This suggests the provider has an outsized role in administering bone-modifying therapy relative to peers and may serve a patient panel with substantial bone-health needs related to oncology.

Administration and chemotherapy-infusion codes (96413, 96401, 96365, 96375, G0498, and 96417) appear throughout the top codes, with 96413 ($63.9K) and 96375 ($10.4K) specifically called out as "notably above typical national volume" for those codes. Coupled with the dominant biologic drug codes, this mix indicates an office-based infusion service line that bills both the drugs themselves and the associated administration services.

The provider also bills a range of supportive-care and diagnostic items—J1568 (IVIG), J0881 (darbepoetin), Q5122 (pegfilgrastim biosimilar), J0185 (aprepitant), J1750 (iron dextran), plus lab panels 85025 and 80053 and flow cytometry 88185—showing an integrated oncology workflow that includes supportive medications and in-office diagnostics. These items are lower share contributors individually but collectively underscore comprehensive oncology management beyond the top immunotherapies.

Outpatient evaluation-and-management volumes are meaningful: 99213 (778 claims, $50.6K, listed as "notably above typical national volume" at the 98th percentile) and 99214 (527 claims, $51.1K, labeled "typical, unremarkable volume" at the 91th percentile) indicate frequent clinic follow-up and ongoing management of established patients. The E/M footprint aligns with a practice that combines longitudinal outpatient care with infusion treatments.

The provider's NPI was enumerated 2009-05-12 (~17 years ago), indicating an established presence in the market. Given the practice's heavy Medicare revenue concentration in a small number of biologic and infusion codes (top three = 75.4% of Medicare revenue), business performance is likely sensitive to utilization shifts or reimbursement changes for those specific drugs and associated infusion services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

82 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	24,000	$40	$1M
J9299	Injection, nivolumab, 1 mg	17,740	$20	$425.8K
J0897	Injection, denosumab, 1 mg	20,520	$20	$369.4K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,730	$30	$123.1K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	39,640	$1	$79.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	630	$100	$63.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	530	$100	$51.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	780	$70	$50.6K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	370	$90	$33.9K
99233	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the…	230	$90	$21.2K

Showing 1–10 of 82

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 82 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Bo Zhao — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

82 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	13	110	12,800	$40	$610.9K
J9299	8	30	12,920	$20	$335.4K
J0897	7	340	2,820	$20	$89.3K
J1568	6	30	1,990	$30	$81.8K
J0881	5	80	10,200	$1	$34.5K
88185	43	60	620	$20	$34.3K
Q5122	11	40	270	$90	$32.5K
96413	14	230	250	$100	$28.5K
J9217	57	130	140	$130	$23.9K
99214	1,795	12,890	140	$80	$21K

Showing 1–10 of 82

Related Providers

Other providers that share a Tax Identification Number (TIN) with Bo Zhao, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Virginia Oncology Associates	VA	Hematology & Oncology Physician	$0	$6.2M
Maryland Oncology Hematology P.A.	MD	Hematology & Oncology Physician	$0	$4.6M
Victor Archie	VA	Radiation Oncology Physician	$4M	$0
Julia Schaefer-cutillo	NC	Hematology & Oncology Physician	$4M	$0
Mark Fleming	VA	Hematology & Oncology Physician	$3.9M	$0
Thomas Alberico	VA	Hematology & Oncology Physician	$3.5M	$0
David Kobulnicky	VA	Hematology & Oncology Physician	$3M	$0
Celesteann Bremer	VA	Hematology & Oncology Physician	$2.8M	$0
Michael Lee	VA	Specialist	$2.3M	$0
Ligeng Tian	VA	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as Bo Zhao, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sentara Hospitals	VA	General Acute Care Hospital	$0	$21.9M
Velocity Urgent Care, LLC	VA	Urgent Care Clinic/Center	$0	$20.9M
Addiction Recovery Center Of Virginia	VA	Clinic/Center	$0	$6M
Evolution Recovery Services LLC	VA	Addiction (Substance Use Disorder) Counselor	$0	$5.6M
John Paschold	VA	Specialist	$1.6M	$0
Surgical Suites Of Coastal Virginia, LLC	VA	Ambulatory Surgical Clinic/Center	$1.3M	$8.7K
Sonia Hepburn	VA	Hematology & Oncology Physician	$1.2M	$0
Audra Albert	VA	Family Nurse Practitioner	$639.8K	$0
Aleisha Johnson	VA	Diagnostic Radiology Physician	$626.6K	$0
Pranav Parikh	VA	Internal Medicine Physician	$579K	$0

Bo Zhao — Billing Profile & Reimbursement Data

Sign up for Bo Zhao — Billing Profile & Reimbursement Data policy alerts

Bo Zhao — Billing Profile & Reimbursement Data

Sign up for Bo Zhao — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References